Syntometrine
ApprovedSmall molecule
Syntometrine is one of 17 small molecule programs targeting Postpartum Hemorrhage. It is currently in Approved.
1
Indications
3
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Postpartum Hemorrhage
#DrugCompanyPhaseTrials
1Cytotec
PfizerApproved
Pitocin
RRetrophin
Approved
Cyklokapron
AAmring
Approved
Folvite
Eli LillyApproved
Syntocinon
SShana McCormack, MD
Approved
Syntometrine
NNorth Bristol NHS Trust
Approved
IV Oxytocin
GSKPhase 3
Pabal
AACADIA Pharmaceuticals Inc.
Preclinical
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 1
Fibrinogen Concentrate
GGold Coast Hospital and Health Service
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Postpartum Hemorrhage1 trial
Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section
Completed·—·Phase 4·NCT02044549·300 enrolled
Obese Women1 trial
Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean
Completed·—·Phase 4·NCT03693599·1,200 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Syntometrine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- NNorth Bristol NHS Trust